Poloxin-2 NEW
| Price | $210 | $582 | $720 |
| Package | 1mg | 5mg | 10mg |
| Supply Ability: | 10g |
| Update Time: | 2026-05-23 |
Product Details
| Product Name: Poloxin-2 | CAS No.: 321695-37-8 |
| Purity: 99.76% | Supply Ability: 10g |
| Release date: 2026/05/23 |
Product Introduction
Bioactivity
| Name | Poloxin-2 |
| Description | Poloxin-2 is a potent and selective Plk1 PBD inhibitor with anti-tumour activity that reduces the protein level of Plk1 in HeLa cells. |
| In vitro | Poloxin-2 increases neurite differentiation of rat NPCs in a dose-dependent manner (EC50=~1 μM) in adherent culture. Under neural sphere-forming conditions, Poloxin-2 (1.5-5 μM) induces neuronal formation in secondary neurospheres derived from adult rat hippocampus and subventricular zone (SVZ) (40-60% TuJ1+ cells).Furthermore, hippocampal NPCs treated with Poloxin-2and cultured on microelectrode arrays for 12 days exhibit neuronal morphology and spontaneous spike activity, indicating the presence of functional, mature neurons[2].In comparison to cells treated with the carrier (dimethyl sulfoxide, DMSO),Poloxin-2 significantly attenuates the growth of tumor cells.TACC3 is a known target of Poloxin-2 in rodent neural progenitor cells. Poloxin-2 has been shown to induce instability in cells expressing TACC3, leading to a gradual reduction in endogenous TACC3 protein levels over time[1]. |
| In vivo | In tumors treated with Poloxin-2, there is a significant reduction in tumor cell proliferation (approximately two-fold decrease). Compared to tumors treated with the carrier control, Poloxin-2-treated tumors show signs of increased cell death (reduced cell structures/increased condensation). Poloxin-2treatment markedly reduces the expansion of frontal-to-tail tumor growth and corpus callosum invasion in waveform protein-positive GBM1 cells. It was also observed that the survival rate of animals carrying GBMX1 tumors (established 2 or 6 weeks prior to treatment) significantly increases with the 10-week Poloxin-2treatment regimen. No mouse had to be removed from the study due to adverse effects of the treatment. Another experiment using continuous Poloxin-2 treatment until the endpoint also shows a significant increase in the survival rate of animals carrying GBMX1 tumors. Histopathological endpoint analysis of animals treated with Poloxin-2 and the vehicle confirms a significant reduction in tumor size in Poloxin-2-treated mice[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 12.5 mg/mL (46.42 mM), Sonication is recommended. |
| Keywords | Poloxin-2 | PLK1 |
| Inhibitors Related | TTK/PLK1-IN-1 | T521 | (E/Z)-Rigosertib sodium | Cyclapolin 9 | SBE13 Hydrochloride | Pyridoxine | Rigosertib sodium | 3MB-PP1 | Ro3280 | Volasertib | BI 2536 | GSK461364 |
| Related Compound Libraries | Bioactive Compound Library | Kinase Inhibitor Library | Post-Translational Modification Compound Library | Inhibitor Library | Bioactive Compounds Library Max | Cell Cycle Compound Library | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
-
CAS:1454920-20-7
-
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $1.10 |
VIP1Y
|
ZHENGZHOU JIUYI TIME NEW MATERIALS CO,.LTD
|
2025-08-18 | |
|
VIP1Y
|
Hefei Lbao Physical & Chemical Science Co.,Ltd
|
2025-11-11 | ||
| $5.00 |
VIP5Y
|
Hebei Chuanghai Biotechnology Co,.LTD
|
2024-08-21 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY